Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ≥59 years: A phase III randomized study

References

• Aye AMM, Bai X, Borrow R, Bory S, Carlos J, Caugant DA, Chiou CS, Dai VTT, Dinleyici EC, Ghimire P, et al. Meningococcal disease surveillance in the Asia–Pacific region (2020): the global meningococcal initiative. J Infect. 2020;81:698–11. doi:10.1016/j.jinf.2020.07.025.
   PubMed Web of Science ®Google Scholar
• Booy R, Gentile A, Nissen M, Whelan J, Abitbol V. Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies. Hum Vaccin Immunother. 2019;15:470–80. doi:10.1080/21645515.2018.1532248.
   PubMed Web of Science ®Google Scholar
• Whittaker R, Dias JG, Ramliden M, Ködmön C, Economopoulou A, Beer N, Pastore Celentano L, Kanitz E, Richter L, Mattheus W, et al. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004–2014. Vaccine. 2017;35:2034–41. doi:10.1016/j.vaccine.2017.03.007.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Enhanced Meningococcal disease surveillance report, 2019: confirmed and probable cases reported to the national notifiable diseases surveillance system. Washington (DC): Office of the Associate Director for Communication, Digital Media Branch, Division of Public Affairs; 2019 [accessed 29 Nov 2022]. https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2019.pdf.
   Google Scholar
• Gunaratnam P, Massey P, Durrheim D, Torvaldsen S. Invasive meningococcal disease in elderly people, New South Wales, Australia, 1993 to 2012. Western Pac Surveill Response J. 2013;4:4–10. doi:10.5365/WPSAR.2013.4.4.001.
   PubMedGoogle Scholar
• Fukusumi M, Kamiya H, Takahashi H, Kanai M, Hachisu Y, Saitoh T, Ohnishi M, Oishi K, Sunagawa T. National surveillance for meningococcal disease in Japan, 1999-2014. Vaccine. 2016;34:4068–71. doi:10.1016/j.vaccine.2016.06.018.
   PubMed Web of Science ®Google Scholar
• Lahra MM, Enriquez RP. Australian Meningococcal Surveillance Programme annual report, 2015. Commun Dis Intell Q Rep. 2016;40:E503–e11.
   PubMed Web of Science ®Google Scholar
• Wang B, Santoreneos R, Giles L, Haji Ali Afzali H, Marshall H. Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis. Vaccine. 2019;37:2768–82. doi:10.1016/j.vaccine.2019.04.020.
   PubMed Web of Science ®Google Scholar
• Guedes S, Bertrand-Gerentes I, Evans K, Coste F, Oster P. Invasive meningococcal disease in older adults in North America and Europe: is this the time for action? A review of the literature. BMC Public Health. 2022;22:380. doi:10.1186/s12889-022-12795-9.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Chapter 4: travel-related infectious diseases. In: Brunette GW, Nemhauser JB, editors. CDC yellow book 2020: health information for international travel. Centers for Disease Control and Prevention (CDC). New York (NY): Oxford University Press; 2020. p. 293–297.
   Google Scholar
• Mbaeyi SA, Bozio CH, Duffy J, Rubin LG, Hariri S, Stephens DS, MacNeil JR. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69:1–41. doi:10.15585/mmwr.rr6909a1.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec. 2011;86:521–40.
   PubMedGoogle Scholar
• Badur S, Khalaf M, Ozturk S, Al-Raddadi R, Amir A, Farahat F, Shibl A. Meningococcal disease and immunization activities in Hajj and Umrah pilgrimage: a review. Infect Dis Ther. 2022;11:1343–69. doi:10.1007/s40121-022-00620-0.
   PubMed Web of Science ®Google Scholar
• Yezli S, Assiri AM, Alhakeem RF, Turkistani AM, Alotaibi B. Meningococcal disease during the Hajj and Umrah mass gatherings. Int J Infect Dis. 2016;47:60–64. doi:10.1016/j.ijid.2016.04.007.
   PubMed Web of Science ®Google Scholar
• Kingdom of Saudi Arabia – Ministry of Health. Health requirements and recommendations for travelers to Saudi Arabia for Hajj and Umrah – 1443H (2022). Ministry of Health – KSA; 2022 [accessed 2022 Nov 29]. https://www.moh.gov.sa/en/HealthAwareness/Pilgrims_Health/Documents/Health-Regulations-En.pdf.
   Google Scholar
• Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62:1–28.
   PubMed Web of Science ®Google Scholar
• Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel MJ, Sullivan K, Gilmet G, Reinhardt A. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Archiv Pediatr Adolesc Med. 2005;159:907–13. doi:10.1001/archpedi.159.10.907.
   PubMed Web of Science ®Google Scholar
• Vu DM, Welsch JA, Zuno-Mitchell P, Dela Cruz JV, Granoff DM. Antibody persistence 3 years after immunization of adolescents with Quadrivalent Meningococcal conjugate vaccine. J Infect Dis. 2006;193:821–28. doi:10.1086/500512.
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Harrison LH, Lynfield R, Reingold A, Schaffner W, Zell ER, Plikaytis B, Wang X, Messonnier NE. Effectiveness and duration of protection of one dose of a Meningococcal conjugate vaccine. Pediatrics. 2017;139:e20162193. doi:10.1542/peds.2016-2193.
   PubMed Web of Science ®Google Scholar
• Rustika R, Oemiati R, Asyary A, Rachmawati T. An evaluation of health policy implementation for Hajj pilgrims in Indonesia. J Epidemiol Glob Health. 2020;10:263–68. doi:10.2991/jegh.k.200411.001.
   PubMed Web of Science ®Google Scholar
• Esteves-Jaramillo A, Koehler T, Jeanfreau R, Neveu D, Jordanov E, Singh Dhingra M. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in >/=56-year-olds: a phase III randomized study. Vaccine. 2020;38:4405–11. doi:10.1016/j.vaccine.2020.04.067.
   PubMed Web of Science ®Google Scholar
• Sanofi. Sanofi Pasteur statement on the discontinuation of Meningococcal polysaccharide vaccine, groups A, C, Y and W-135 combined. Bridgewater (NJ): Sanofi US; 2017 Feb 9 [accessed 2022 Nov 29]. https://www.news.sanofi.us/Sanofi-Pasteur-Statement-on-the-Discontinuation-of-Meningococcal-Polysaccharide-Vaccine-Groups-A-C-Y-and-W-135-Combined.
   Google Scholar
• Trzewikoswki de Lima G, De Gaspari E. Study of the immune response in the elderly: is it necessary to develop a vaccine against Neisseria meningitidis for the aged? J Aging Res. 2019;2019:9287121. doi:10.1155/2019/9287121.
   PubMedGoogle Scholar
• Lord JM. The effect of ageing of the immune system on vaccination responses. Hum Vaccin Immunother. 2013;9:1364–67. doi:10.4161/hv.24696.
   PubMed Web of Science ®Google Scholar
• Kirstein J, Pina M, Pan J, Jordanov E, Dhingra MS. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adults 56 years of age and older: a Phase II randomized study. Hum Vaccin Immunother. 2020;16:1299–305. doi:10.1080/21645515.2020.1733868.
   PubMed Web of Science ®Google Scholar
• Pina LM, Bassily E, Machmer A, Hou V, Reinhardt A. Safety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants and toddlers: three multicenter phase III studies. Pediatr Infect Dis J. 2012;31:1173–83. doi:10.1097/INF.0b013e318268dfe4.
   PubMed Web of Science ®Google Scholar
• Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, Arhin FF, Devi SJ, Frasch CE, Huang JC, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup a and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol. 1997;4:156–67. doi:10.1128/cdli.4.2.156-167.1997.
   PubMedGoogle Scholar
• Anez G, Hedrick J, Simon MW, Christensen S, Jeanfreau R, Yau E, Pan J, Jordanov E, Dhingra MS. Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a phase III randomized study. Hum Vaccin Immunother. 2020;16:1292–98. doi:10.1080/21645515.2020.1733867.
   PubMed Web of Science ®Google Scholar
• Piazza FM, Virta M, Paassilta M, Ukkonen B, Ahonen A, Esteves-Jaramillo A, Forsten A, Seppa I, Ding J, Neveu D, et al. Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: a phase III, open-label, multi-center study. Hum Vaccin Immunother. 2021;1–10. doi:10.1080/21645515.2021.1902701
   PubMed Web of Science ®Google Scholar
• Dbaibo G, El-Ayoubi N, Ghanem S, Hajar F, Bianco V, Miller JM, Mesaros N. Immunogenicity and safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) administered to adults aged 56 years and older: results of an open-label, randomized, controlled trial. Drugs Aging. 2013;30:309–19. doi:10.1007/s40266-013-0065-0.
   PubMed Web of Science ®Google Scholar
• Stamboulian D, Lopardo G, Lopez P, Cortes-Barbosa C, Valencia A, Bedell L, Karsten A, Dull PM. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America. Int J Infect Dis. 2010;14:e868–75. doi:10.1016/j.ijid.2010.03.017.
   PubMed Web of Science ®Google Scholar
• Bröker M, Berti F, Schneider J, Vojtek I. Polysaccharide conjugate vaccine protein carriers as a “neglected valency” – potential and limitations. Vaccine. 2017;35:3286–94. doi:10.1016/j.vaccine.2017.04.078.
   PubMed Web of Science ®Google Scholar
• Pace D. Glycoconjugate vaccines. Expert Opin Biol Ther. 2013;13:11–33. doi:10.1517/14712598.2012.725718.
   PubMed Web of Science ®Google Scholar
• Bilukha OO, Rosenstein N. National Center for Infectious Diseases CFDC and Prevention. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2005;54:1–21.
   PubMedGoogle Scholar
• Findlow J, Balmer P, Borrow R. A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines. Hum Vaccin Immunother. 2019;15:2491–500. doi:10.1080/21645515.2019.1593082.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. EPAR summary for the public. Menveo meningococcal group A, C, W135 and Y conjugate vaccine. European Medicines Agency, 2015. Report no: EMA/595072/2015. [accessed 29 Nov 2022]. https://www.ema.europa.eu/en/medicines/human/EPAR/menveo.
   Google Scholar
• European Medicnes Agency. EPAR summary for the public. Nimenrix (meningococcal groups A, C, W-135 and Y conjugate vaccine). European Medicines Agency, 2019. Report no: EMA/402486/2019. [accessed 29 Nov 2022]. https://www.ema.europa.eu/en/medicines/human/EPAR/nimenrix.
   Google Scholar
• Vesikari T, Borrow R, Forsten A, Findlow H, Dhingra MS, Jordanov E. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a phase II randomized study. Hum Vacc Immunotherap. 2020;16:1306–12. doi:10.1080/21645515.2020.1733869.
   PubMed Web of Science ®Google Scholar